This site is intended for healthcare professionals
News

Brilinta monotherapy reduced the risk of clinically relevant bleeding compared to aspirin + Brilinta in high-risk coronary patients according to phase IV independent TWILIGHT trial. AstraZeneca

Read time: 1 mins
Published:31st Mar 2020
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.
Condition: Acute Coronary Syndrome
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest